<DOC>
	<DOC>NCT01305512</DOC>
	<brief_summary>Evaluation of pharmacokinetic profile of SPARC1028</brief_summary>
	<brief_title>Pharmacokinetic, Safety and Tolerability Study of SPARC1028</brief_title>
	<detailed_description>This is a phase I study of SPARC1028 and recommend phase II dose of SPARC1028 administered once a week for 3 weeks, followed by 1 week of rest.</detailed_description>
	<criteria>Histologically or cytologically confirmed diagnosis of solid tumor in advanced stage which taxanebased therapy is a rational treatment option. Age ≥18 years ECOG Performance Status ≤ 1. Estimated life expectancy of at least 12weeks; Any malignancy within past 5years, except nonmelanoma skin cancer, cervical intraepithelial neoplasia, or in situ cervical cancer Known hypersensitivity to the study drugs Treatment with any anticancer agents within 28 days of study entry Presence of clinically evident active CNS metastases, including leptomeningeal involvement, requiring steroid or radiation therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Solid</keyword>
	<keyword>Tumor</keyword>
	<keyword>Taxane</keyword>
</DOC>